Al­to Neu­ro­science and Fractyl Health add to biotech IPO mo­men­tum in Fri­day dou­ble­head­er

Last year
Financing
Startups

Take­da says farewell to CFO, suite of clin­i­cal-stage pro­grams in Q3 up­date

Last year
R&D
Pharma

Pub­li­cis Health set­tles opi­oid law­suit

Last year
Pharma
Marketing

Ex­clu­sive: Col­umn Group rais­es a new $400M+ fund and R&D hub for sin­gle-as­set bi­o­log­ics com­pa­nies

Last year
Financing
Startups

Mer­ck high­lights sub­cu­ta­neous de­mand even as Keytru­da sales soar

Last year
Pharma

Just how low did the gov­ern­ment go with first IRA of­fers? Phar­ma’s not telling

Last year
Pharma

AGC Bi­o­log­ics hit with 483 for poor dis­crep­an­cy in­ves­ti­ga­tion prac­tices, qual­i­ty con­trol is­sues at Wash­ing­ton site

Last year
Pharma
FDA+

Cor­rect­ed: Bi­par­ti­san IRA fix seeks to align small mol­e­cule and bi­o­log­ic ne­go­ti­a­tion pe­ri­ods

Last year
Pharma

Up­dat­ed: Law­suit ac­cus­es UPenn and Jim Wil­son of se­cret­ly prof­it­ing from for­mer post­doc's work

Last year
People
Law

Mer­ck still on the hunt for bil­lion-dol­lar deals, cit­ing Prometheus and Dai­ichi Sankyo as ex­am­ples

Last year
Deals
Pharma

Bask­ing rais­es $55M; Ser­o­ba’s fourth fund; Ve­ra up­sizes its pub­lic of­fer­ing

Last year
News Briefing

Schrödinger takes a step for­ward with Al­phaFold in drug R&D, as biotech hits a pipeline 'in­flec­tion'

Last year
R&D
AI

Ther­mo Fish­er mulls Irish site ex­it; Alvotech’s new Form 483; Catal­ent as­sists with We­govy man­u­fac­tur­ing

Last year
Manufacturing

Amid GLP-1 ma­nia, health tech's weight loss star­tups are try­ing to prove their ser­vices mat­ter

Last year
Health Tech

Due to ‘over­whelm­ing de­mand,’ Sanofi and As­traZeneca’s RSV an­ti­body to be in lim­it­ed sup­ply 

Last year
Pharma
Manufacturing

Kyver­na seeks $182M IPO as biotech runs mul­ti­ple au­toim­mune CAR-T tri­als

Last year
Financing
Cell/Gene Tx

Take­da wa­gers $300M on Pro­tag­o­nist’s PhI­II rare dis­ease drug

Last year
Deals

Biotech deal­mak­ing shows some signs of a turn­around. And the in­dus­try is keep­ing its fin­gers crossed

Last year
Bioregnum

Flash back: Astel­las re­turns to the Su­per Bowl with menopause mes­sage

Last year
Pharma
Marketing

‘120 pages of da­ta’: Roche’s pipeline re­view leads to as­set cuts, but al­so ad­di­tions

Last year
R&D
Pharma

Up­dat­ed: Mer­ck gives few de­tails on 2024 re­struc­tur­ing plan for man­u­fac­tur­ing net­work

Last year
Pharma
Manufacturing

‘Watch this evolve’: Sanofi con­tin­ues to talk up its R&D bet as Paul Hud­son wel­comes new CFO

Last year
R&D
Pharma

'Sys­temic' changes com­ing to ad­vi­so­ry com­mit­tee process, FDA com­mis­sion­er says

Last year
FDA+

Eli Lil­ly dou­bles down on health eq­ui­ty in new cor­po­rate cam­paign

Last year
Pharma
Marketing
First page Previous page 208209210211212213214 Next page Last page
A service from the Financial Times